Viral Pneumonia: From Influenza to COVID-19

Catia Cilloniz; Guinevere Dy-Agra; Rodolfo S. Pagcatipunan Jr.; Antoni Torres

doi:10.1055/s-0043-1777796

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2024; 45(02): 207-224
DOI: 10.1055/s-0043-1777796

Review Article

Viral Pneumonia: From Influenza to COVID-19

Catia Cilloniz

¹Hospital Clinic of Barcelona, IDIBAPS, CIBERESA, Barcelona, Spain

²Faculty of Health Sciences, Continental University, Huancayo, Peru

,

Guinevere Dy-Agra

³Institute of Pulmonary Medicine, St Luke's Medical Center—Global City, Taguig, Metro Manila, Philippines

,

Rodolfo S. Pagcatipunan Jr.

³Institute of Pulmonary Medicine, St Luke's Medical Center—Global City, Taguig, Metro Manila, Philippines

,

Antoni Torres

¹Hospital Clinic of Barcelona, IDIBAPS, CIBERESA, Barcelona, Spain

⁴School of Medicine, University of Barcelona, Barcelona, Spain

› Institutsangaben

Abstract

Respiratory viruses are increasingly recognized as a cause of community-acquired pneumonia (CAP). The implementation of new diagnostic technologies has facilitated their identification, especially in vulnerable population such as immunocompromised and elderly patients and those with severe cases of pneumonia. In terms of severity and outcomes, viral pneumonia caused by influenza viruses appears similar to that caused by non-influenza viruses. Although several respiratory viruses may cause CAP, antiviral therapy is available only in cases of CAP caused by influenza virus or respiratory syncytial virus. Currently, evidence-based supportive care is key to managing severe viral pneumonia. We discuss the evidence surrounding epidemiology, diagnosis, management, treatment, and prevention of viral pneumonia.

Keywords

respiratory viruses - virus - COVID-19 - viral pneumonia - infection

Volltext

Referenzen

References
1 Torres A, Lee N, Cilloniz C, Vila J, Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J 2016; 48 (06) 1764-1778
2 Cilloniz C, Luna CM, Hurtado JC, Marcos MÁ, Torres A. Respiratory viruses: their importance and lessons learned from COVID-19. Eur Respir Rev 2022; 31 (166) 220051
3 Torres A, Cilloniz C, Niederman MS. et al. Pneumonia. Nat Rev Dis Primers 2021; 7 (01) 25
4 Gao CA, Pickens CI, Morales-Nebreda L, Wunderink RG. Clinical features of COVID-19 and differentiation from other causes of CAP. Semin Respir Crit Care Med 2023; 44 (01) 8-20
5 WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited April 11, 2023]. Accessed November 20, 2023 at: https://covid19.who.int
6 Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. Lancet 2022; 400 (10353): 693-706
7 Franczuk P, Tkaczyszyn M, Kulak M, Domenico E, Ponikowski P, Jankowska EA. Cardiovascular complications of viral respiratory infections and COVID-19. Biomedicines 2022; 11 (01) 71
8 Caldeira D, Nogueira-Garcia B. Myocardial infarction and viral triggers: what do we know by now?. Eur Heart J Suppl 2023; 25 (Suppl A): A12-A16
9 Seeherman S, Suzuki YJ. Viral infection and cardiovascular disease: implications for the molecular basis of COVID-19 pathogenesis. Int J Mol Sci 2021; 22 (04) 1659
10 Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med 2019; 380 (02) 171-176
11 Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J 2018; 51 (03) 1701794
12 Jain S, Self WH, Wunderink RG. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
13 Cillóniz C, Pericàs JM, Rojas JR, Torres A. Severe infections due to respiratory viruses. Semin Respir Crit Care Med 2022; 43 (01) 60-74
14 Piralla A, Mariani B, Rovida F, Baldanti F. Frequency of respiratory viruses among patients admitted to 26 intensive care units in seven consecutive winter-spring seasons (2009-2016) in Northern Italy. J Clin Virol 2017; 92: 48-51
15 Bianchini S, Silvestri E, Argentiero A, Fainardi V, Pisi G, Esposito S. Role of respiratory syncytial virus in pediatric pneumonia. Microorganisms 2020; 8 (12) 8
16 Torres A, Cilloniz C, Niederman MS. et al. Pneumonia. Nat Rev Dis Primers 2021; 7 (01) 25
17 Luna CM, Famiglietti A, Absi R. et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118 (05) 1344-1354
18 Cillóniz C, Ewig S, Polverino E. et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66 (04) 340-346
19 Cillóniz C, Dominedò C, Magdaleno D, Ferrer M, Gabarrús A, Torres A. Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis 2019; 220 (07) 1166-1171
20 Karhu J, Ala-Kokko TI, Vuorinen T, Ohtonen P, Syrjälä H. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis 2014; 59 (01) 62-70
21 Nguyen C, Kaku S, Tutera D, Kuschner WG, Barr J. Viral respiratory infections of adults in the intensive care unit. J Intensive Care Med 2016; 31 (07) 427-441
22 Choi S-H, Hong S-B, Ko G-B. et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012; 186 (04) 325-332
23 Hasvold J, Sjoding M, Pohl K, Cooke C, Hyzy RC. The role of human metapneumovirus in the critically ill adult patient. J Crit Care 2016; 31 (01) 233-237
24 Garg S, Jain S, Dawood FS. et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005–2008. BMC Infect Dis [Internet] 2015 [cited Jan 25, 2021]. Accessed November 20, 2023 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550040/
25 Ljungström LR, Jacobsson G, Claesson BEB, Andersson R, Enroth H. Respiratory viral infections are underdiagnosed in patients with suspected sepsis. Eur J Clin Microbiol Infect Dis 2017; 36 (10) 1767-1776
26 Hartman L, Zhu Y, Edwards KM, Griffin MR, Talbot HK. Underdiagnosis of influenza virus infection in hospitalized older adults. J Am Geriatr Soc 2018; 66 (03) 467-472
27 Vanhems P, Bénet T, Munier-Marion E. Nosocomial influenza: encouraging insights and future challenges. Curr Opin Infect Dis 2016; 29 (04) 366-372
28 Loubet P, Voiriot G, Houhou-Fidouh N. et al. Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: a single-center retrospective study. J Clin Virol 2017; 91: 52-57
29 Kapandji N, Darmon M, Valade S. et al. Clinical significance of human metapneumovirus detection in critically ill adults with lower respiratory tract infections. Ann Intensive Care 2023; 13 (01) 21
30 Micek ST, Chew B, Hampton N, Kollef MH. A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest 2016; 150 (05) 1008-1014
31 Shorr AF, Fisher K, Micek ST, Kollef MH. The burden of viruses in pneumonia associated with acute respiratory failure: an underappreciated issue. Chest 2018; 154 (01) 84-90
32 Shorr AF, Ilges DT, Micek ST, Kollef MH. The importance of viruses in ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2022;
33 Zou Q, Zheng S, Wang X. et al. Influenza A-associated severe pneumonia in hospitalized patients: risk factors and NAI treatments. Int J Infect Dis 2020; 92: 208-213
34 Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol 2021; 19 (07) 425-441
35 Grasselli G, Greco M, Zanella A. et al; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180 (10) 1345-1355
36 Cilloniz C, Ferrer M, Pericàs JM. et al Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia. Arch Bronconeumol 2023; 59 (01) 19-26
37 Cillóniz C, Dominedò C, Pericàs JM, Rodriguez-Hurtado D, Torres A. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev 2020; 29 (155) 190126
38 Goeijenbier M, van Wissen M, van de Weg C. et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012; 84 (10) 1680-1696
39 Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep 2020; 22 (09) 63
40 Armstrong SM, Darwish I, Lee WL. Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection. Virulence 2013; 4 (06) 537-542
41 Li H, Liu L, Zhang D. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395 (10235): 1517-1520
42 Lin HY. Why does the sepsis induced by severe COVID-19 have different clinical features from sepsis induced by CrKP?. Chin J Traumatol 2022; 25 (01) 25-26
43 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280 (05) E745-E751
44 Tartof SY, Qian L, Hong V. et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med 2020; 173 (10) 773-781
45 Kompaniyets L, Pennington AF, Goodman AB. et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis 2021; 18: E66
46 Reid A. The effects of the 1918-1919 influenza pandemic on infant and child health in Derbyshire. Med Hist 2005; 49 (01) 29-54
47 Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol 2012; 207 (3, Suppl): S3-S8
48 Martinez-Portilla RJ, Sotiriadis A, Chatzakis C. et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol 2021; 57 (02) 224-231
49 Villar J, Ariff S, Gunier RB. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID Multinational Cohort Study. JAMA Pediatr 2021; 175 (08) 817-826
50 Moreno-García E, Puerta-Alcalde P, Letona L. et al. Bacterial co-infection at hospital admission in patients with COVID-19. Int J Infect Dis [Internet] 2022 [cited March 18, 2022]. Accessed November 20, 2023 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896874/
51 Chen Z, Zhan Q, Huang L, Wang C. Coinfection and superinfection in ICU critically ill patients with severe COVID-19 pneumonia and influenza pneumonia: are the pictures different?. Front Public Health 2023; 11: 1195048
52 Rouzé A, Lemaitre E, Martin-Loeches I. et al; coVAPid Study Group. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. Crit Care 2022; 26 (01) 11
53 Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol 2017; 8: 1041
54 Rice TW, Rubinson L, Uyeki TM. et al; NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40 (05) 1487-1498
55 Mulcahy ME, McLoughlin RM. Staphylococcus aureus and influenza A virus: partners in coinfection. MBio 2016; 7 (06) e02068-e16
56 Wauters J, Baar I, Meersseman P. et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 2012; 38 (11) 1761-1768
57 Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198 (07) 962-970
58 Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58 (38) 1071-1074
59 Martín-Loeches I, Sanchez-Corral A, Diaz E. et al; H1N1 SEMICYUC Working Group. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011; 139 (03) 555-562
60 Taccone FS, Van den Abeele A-M, Bulpa P. et al; AspICU Study Investigators. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care 2015; 19 (01) 7
61 Schauwvlieghe AFAD, Rijnders BJA, Philips N. et al; Dutch-Belgian Mycosis Study Group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6 (10) 782-792
62 Janssen NAF, Nyga R, Vanderbeke L. et al. Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis. Emerg Infect Dis 2021; 27 (11) 2892-2898
63 Liu R-T, Chen Y, Li S. et al. A comparison of diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. Infect Dis Ther 2023; 12 (06) 1641-1653
64 Gregianini TS, Varella IRS, Fisch P, Martins LG, Veiga ABG. Dual and triple infections with influenza A and B viruses: a case-control study in Southern Brazil. J Infect Dis 2019; 220 (06) 961-968
65 Nickbakhsh S, Thorburn F, VON Wissmann B, McMenamin J, Gunson RN, Murcia PR. Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections. Epidemiol Infect 2016; 144 (10) 2064-2076
66 Goka E, Vallely P, Mutton K, Klapper P. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. Influenza Other Respir Viruses 2013; 7 (06) 1079-1087
67 Asner SA, Science ME, Tran D, Smieja M, Merglen A, Mertz D. Clinical disease severity of respiratory viral co-infection versus single viral infection: a systematic review and meta-analysis. PLoS One 2014; 9 (06) e99392
68 Haney J, Vijayakrishnan S, Streetley J. et al. Coinfection by influenza A virus and respiratory syncytial virus produces hybrid virus particles. Nat Microbiol 2022; 7 (11) 1879-1890
69 Lew S, Manes P, Smith B. Coinfection with SARS-CoV-2 and influenza A virus in a 32-year-old man. Am J Case Rep 2020; 21: e926092
70 Cheng Y, Ma J, Wang H. et al. Co-infection of influenza A virus and SARS-CoV-2: a retrospective cohort study. J Med Virol 2021; 93 (05) 2947-2954
71 Bai L, Zhao Y, Dong J. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res 2021; 31 (04) 395-403
72 Korsun N, Trifonova I, Dobrinov V, Madzharova I, Grigorova I, Christova I. Low prevalence of influenza viruses and predominance of A(H3N2) virus with respect to SARS-CoV-2 during the 2021-2022 season in Bulgaria. J Med Virol 2023; 95 (02) e28489
73 Mak GCK, Lau SSY, Wong KKY, Lau AWL, Hung DLL. Low prevalence of seasonal influenza viruses in Hong Kong, 2022. Influenza Other Respir Viruses 2023; 17 (03) e13123
74 Dhanasekaran V, Sullivan S, Edwards KM. et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun 2022; 13 (01) 1721
75 Gomez GB, Mahé C, Chaves SS. Uncertain effects of the pandemic on respiratory viruses. Science 2021; 372 (6546): 1043-1044
76 van Asten L, Luna Pinzon A, van de Kassteele J. et al. The association between influenza infections in primary care and intensive care admissions for severe acute respiratory infection (SARI): a modelling approach. Influenza Other Respir Viruses 2020; 14 (05) 575-586
77 van Asten L, Luna Pinzon A, de Lange DW. et al. Estimating severity of influenza epidemics from severe acute respiratory infections (SARI) in intensive care units. Crit Care 2018; 22 (01) 351
78 CDC. 2019–2020 U.S. Flu Season: Preliminary in-Season Burden Estimates [Internet]. 2021. Accessed November 20, 2023 at: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
79 Weekly US Influenza Surveillance Report [Internet]. Centers for Disease Control and Prevention 2023 [cited May 2, 2023]. Accessed November 20, 2023 at: https://www.cdc.gov/flu/weekly/index.htm
80 CDC. 2009 H1N1 Pandemic (H1N1pdm09 virus) [Internet]. Accessed November 20, 2023 at: https://www.cdc.gov/flu/pandemic-resources/2009-h1n1-pandemic.html
81 Hong H-L, Hong S-B, Ko G-B. et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One 2014; 9 (04) e95865
82 van Someren Gréve F, Juffermans NP, Bos LDJ. et al. Respiratory viruses in invasively ventilated critically ill patients - a prospective multicenter observational study. Crit Care Med 2018; 46 (01) 29-36
83 Herold S, Becker C, Ridge KM, Budinger GRS. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J 2015; 45 (05) 1463-1478
84 Rodríguez A, Díaz E, Martín-Loeches I. et al; H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66 (05) 1140-1149
85 Short KR, Kroeze EJBV, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 2014; 14 (01) 57-69
86 Baral N, Adhikari P, Adhikari G, Karki S. Influenza myocarditis: a literature review. Cureus 2020; 12 (12) e12007
87 Álvarez-Lerma F, Marín-Corral J, Vila C. et al; H1N1 GETGAG/SEMICYUC Study Group. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome. Crit Care 2016; 20 (01) 337
88 Cillóniz C, Civljak R, Nicolini A, Torres A. Polymicrobial community-acquired pneumonia: an emerging entity. Respirology 2016; 21 (01) 65-75
89 Klein EY, Monteforte B, Gupta A. et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016; 10 (05) 394-403
90 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
91 Uyeki TM, Bernstein HH, Bradley JS. et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68 (06) e1-e47
92 Casalino E, Antoniol S, Fidouh N. et al. Influenza virus infections among patients attending emergency department according to main reason to presenting to ED: a 3-year prospective observational study during seasonal epidemic periods. PLoS One 2017; 12 (08) e0182191
93 Maruyama T, Fujisawa T, Suga S. et al. Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: a prospective multicenter cohort study. Chest 2016; 149 (02) 526-534
94 Abaziou T, Delmas C, Vardon Bounes F. et al. Outcome of critically ill patients with influenza infection: a retrospective study. Infect Dis (Auckl) 2020; 13: 1178633720904081
95 Yi G, de Kraker MEA, Buetti N. et al. Risk factors for in-hospital mortality and secondary bacterial pneumonia among hospitalized adult patients with community-acquired influenza: a large retrospective cohort study. Antimicrob Resist Infect Control 2023; 12 (01) 25
96 Bonmarin I, Belchior E, Bergounioux J. et al. Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. Euro Surveill 2015; 20 (46) 20
97 Pronier C, Gacouin A, Lagathu G, Le Tulzo Y, Tadié J-M, Thibault V. Respiratory influenza viral load as a marker of poor prognosis in patients with severe symptoms. J Clin Virol 2021; 136: 104761
98 Claverias L, Daniel X, Martín-Loeches I. et al; GETGAG/SEMICYUC Working Group. Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia. Med Intensiva (Engl Ed) 2022; 46 (08) 426-435
99 Zhou F, Wang Y, Liu Y. et al; CAP-China Network. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J 2019; 54 (02) 1802406
100 Chen L, Han X-D, Li Y-L, Zhang C-X, Xing X-Q. Comparison of the clinical characteristics and severity of influenza and non-influenza respiratory virus-related pneumonia in China: a multicenter, real-world study. Infect Drug Resist 2020; 13: 3513-3523
101 Choi S-H, Huh JW, Hong S-B. et al. Clinical characteristics and outcomes of severe rhinovirus-associated pneumonia identified by bronchoscopic bronchoalveolar lavage in adults: comparison with severe influenza virus-associated pneumonia. J Clin Virol 2015; 62: 41-47
102 Choi S-H, Hong S-B, Huh JW. et al. Outcomes of severe human metapneumovirus-associated community-acquired pneumonia in adults. J Clin Virol 2019; 117: 1-4
103 Vidaur L, Totorika I, Montes M, Vicente D, Rello J, Cilla G. Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis. Ann Intensive Care 2019; 9 (01) 86
104 Coussement J, Zuber B, Garrigues E. et al. Characteristics and outcomes of patients in the ICU with respiratory syncytial virus compared with those with influenza infection: a multicenter matched cohort study. Chest 2022; 161 (06) 1475-1484
105 Lynch III JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med 2016; 37 (04) 586-602
106 Branche AR, Falsey AR. Parainfluenza virus infection. Semin Respir Crit Care Med 2016; 37 (04) 538-554
107 Fragkou PC, Moschopoulos CD, Karofylakis E, Kelesidis T, Tsiodras S. Update in Viral Infections in the Intensive Care Unit. Front Med (Lausanne) [Internet] 2021 [cited April 1, 2021]. Accessed November 20, 2023 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940368/
108 Di Pasquale MF, Sotgiu G, Gramegna A. et al; GLIMP Investigators. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis 2019; 68 (09) 1482-1493
109 Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43 (03) 331-339
110 Dudding BA, Wagner SC, Zeller JA, Gmelich JT, French GR, Top Jr FH. Fatal pneumonia associated with adenovirus type 7 in three military trainees. N Engl J Med 1972; 286 (24) 1289-1292
111 Zhao J, Yap A, Wu E, Low CY, Yap J. Severe community acquired adenovirus pneumonia in an immunocompetent host successfully treated with IV Cidofovir. Respir Med Case Rep 2020; 30: 101037
112 Barker JH, Luby JP, Sean Dalley A, Bartek WM, Burns DK, Erdman DD. Fatal type 3 adenoviral pneumonia in immunocompetent adult identical twins. Clin Infect Dis 2003; 37 (10) e142-e146
113 Evans SE, Jennerich AL, Azar MM. et al. Nucleic acid-based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2021; 203 (09) 1070-1087
114 de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14 (08) 523-534
115 Coronavirus Resource Center [Internet]. Johns Hopkins Coronavirus Resource Center [cited April 12, 2021]. Accessed November 20, 2023 at: https://coronavirus.jhu.edu/
116 Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020; 94: 119-124
117 Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: a systematic review. Wellcome Open Res 2020; 5: 94
118 Carignan A, Valiquette L, Grenier C. et al. Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study. CMAJ 2020; 192 (26) E702-E707
119 Dev N, Sankar J, Gupta N. et al. COVID-19 with and without anosmia or dysgeusia: a case-control study. J Med Virol 2021; 93 (04) 2499-2504
120 Eshraghi AA, Mirsaeidi M, Davies C, Telischi FF, Chaudhari N, Mittal R. Potential mechanisms for COVID-19 induced anosmia and dysgeusia. Front Physiol 2020; 11: 1039
121 Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19 (03) 141-154
122 Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis 2020; 71 (16) 2199-2206
123 Petrilli CM, Jones SA, Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966
124 Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J. et al Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect 2020; Nov; 26 (11) 1525-1536
125 Cilloniz C, Pericàs JM, Motos A, Gabarrús A, Ferrer R. et al Hyperglycemia in Acute Critically Ill COVID-19 Patients. Arch Bronconeumol 2023; Jan; 59 (01) 51-56
126 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05) 475-481
127 Xu J, Yang X, Yang L. et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care 2020; 24 (01) 394
128 Ferrando C, Mellado-Artigas R, Gea A. et al; de la Red de UCI Española para COVID-19. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, . multicentre study [in Spanish]. Rev Esp Anestesiol Reanim (Engl Ed) 2020; 67 (08) 425-437
129 Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol 2020; 92 (06) 612-617
130 Banfi P, Garuti G, Diaz de Teran T. et al. Differences between sexes concerning COVID-19-related pneumonia. Panminerva Med 2022; 64 (04) 517-524
131 Michels EHA, Appelman B, de Brabander J. et al; Amsterdam UMC COVID-19 Biobank Study Group, Amsterdam UMC COVID-19 Biobank Study Group. Age-related changes in plasma biomarkers and their association with mortality in COVID-19. Eur Respir J 2023; 62 (01) 2300011
132 Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020; 20 (06) 689-696
133 Garazzino S, Lo Vecchio A, Pierantoni L. et al; Italian SITIP-SIP Pediatric Infection Study Group. Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: results from an Italian Multicenter Study. Front Pediatr 2021; 9: 649358
134 Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: a scoping review. J Pediatr Rehabil Med 2020; 13 (03) 301-316
135 García-Salido A, de Carlos Vicente JC, Belda Hofheinz S. et al; Spanish Pediatric Intensive Care Society Working Group on SARS-CoV-2 Infection. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care 2020; 24 (01) 666
136 Pereira MFB, Litvinov N, Farhat SCL. et al; Pediatric COVID HC-FMUSP Study Group. Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome. Clinics (São Paulo) 2020; 75: e2209
137 Sık G, Inamlık A, Akçay N. et al; Turkish MIS-C Study Group. Mortality risk factors among critically ill children with MIS-C in PICUs: a multicenter study. Pediatr Res 2023; 94 (02) 730-737
138 Vogel TP, Top KA, Karatzios C. et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2021; 39 (22) 3037-3049
139 Patel P, DeCuir J, Abrams J, Campbell AP, Godfred-Cato S, Belay ED. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review. JAMA Netw Open 2021; 4 (09) e2126456
140 Bhatt VR, Jawade PG, Patel AM, Palange A, Adapa S. Post-COVID multisystem inflammatory syndrome-adult leading to cardiomyopathy and autoimmune thyroiditis: a case report. Cureus 2023; 15 (01) e33754
141 Bermejo-Martin JF, García-Mateo N, Motos A. et al; CIBERES-UCI-COVID Group. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study. Lancet Microbe 2023; 4 (06) e431-e441
142 Losier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia. Curr Opin Infect Dis 2022; 35 (02) 128-132
143 Vos LM, Bruning AHL, Reitsma JB. et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis 2019; 69 (07) 1243-1253
144 Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323 (18) 1843-1844
145 Healthcare Workers [Internet]. Centers for Disease Control and Prevention 2020 [cited May 13, 2023]. Accessed November 20, 2023 at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
146 Deshpande A, Klompas M, Yu P-C. et al. Influenza testing and treatment among patients hospitalized with community-acquired pneumonia. Chest 2022; 162 (03) 543-555
147 Sur M, Lopez MJ, Baker MB. Oseltamivir. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021 [cited June 21, 2021]. Accessed November 20, 2023 at: http://www.ncbi.nlm.nih.gov/books/NBK539909/
148 Muthuri SG, Venkatesan S, Myles PR. et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2 (05) 395-404
149 Moreno G, Rodríguez A, Sole-Violán J. et al. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Res [Internet] 2021 [cited March 23, 2021]. Accessed November 20, 2023 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938052/
150 Behillil S, May F, Fourati S. et al. Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study. Clin Infect Dis 2020; 71 (04) 1089-1091
151 Lina B, Boucher C, Osterhaus A. et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza Other Respir Viruses 2018; 12 (02) 267-278
152 Marty FM, Vidal-Puigserver J, Clark C. et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017; 5 (02) 135-146
153 Chen H-D, Wang X, Yu S-L, Ding Y-H, Wang M-L, Wang J-N. Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study. Open Forum Infect Dis [Internet] 2020 [cited April 12, 2021]. Accessed November 20, 2023 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793458/
154 Hsieh YH, Dugas AF, LoVecchio F. et al. Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: results from a pilot randomized controlled study. Influenza Other Respir Viruses 2021; 15 (01) 121-131
155 Hayden FG, Sugaya N, Hirotsu N. et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379 (10) 913-923
156 Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med 2018; 66 (06) 957-965
157 Wongsurakiat P, Sunhapanit S, Muangman N. Respiratory syncytial virus-associated acute respiratory illness in adult non-immunocompromised patients: Outcomes, determinants of outcomes, and the effect of oral ribavirin treatment. Influenza Other Respir Viruses 2022; 16 (04) 767-779
158 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020; 383 (19) 1813-1826
159 Pan H, Peto R, Henao-Restrepo A-M. et al; WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384 (06) 497-511
160 Paxlovid for Treatment of COVID-19 | The Medical Letter Inc. [Internet]. [cited May 9, 2023]. Accessed November 20, 2023 at: https://secure.medicalletter.org/TML-article-1642a
161 Hospitalized Adults. Therapeutic Management [Internet]. COVID-19 Treatment Guidelines [cited May 13, 2023]. Accessed November 20, 2023 at: https://www.covid19treatmentguidelines.nih.gov/tables/therapeutic-management-of-hospitalized-adults/
162 WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022; 399 (10339): 1941-1953
163 Ali K, Azher T, Baqi M. et al; Canadian Treatments for COVID-19 (CATCO), Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022; 194 (07) E242-E251
164 Wolfe CR, Tomashek KM, Patterson TF. et al; ACTT-4 Study Group. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med 2022; 10 (09) 888-899
165 Cillóniz C, Motos A, Castañeda T, Gabarrús A, Barbé F, Torres A. CIBERESUCICOVID Project (COV20/00110, ISCIII). Remdesivir and survival outcomes in critically ill patients with COVID-19: a multicentre observational cohort study. J Infect 2023; 86 (03) 256-308
166 Martin-Loeches I, Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. Eur Respir Rev 2021; 30 (159) 30
167 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2 (02) CD010406
168 Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019; 23 (01) 99
169 Wang Y, Guo Q, Yan Z. et al; CAP-China Network. Factors associated with prolonged viral shedding in patients with avian influenza A (H7N9) virus infection. J Infect Dis 2018; 217 (11) 1708-1717
170 Zhou Y, Fu X, Liu X. et al. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep 2020; 10 (01) 3044
171 Moreno G, Rodríguez A, Reyes LF. et al; GETGAG Study Group. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 2018; 44 (09) 1470-1482
172 Okuno D, Kido T, Muramatsu K. et al. Impact of corticosteroid administration within 7 days of the hospitalization for influenza pneumonia with respiratory failure: a propensity score analysis using a nationwide administrative database. J Clin Med 2021; 10 (03) 10
173 Therapeutic Management [Internet]. COVID-19 Treatment Guidelines [cited April 12, 2021]. Accessed November 20, 2023 at: https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/
174 Therapeutics and COVID-19: living guideline [Internet]. [cited April 12, 2021]. Accessed November 20, 2023 at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2021.1
175 The RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR. et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384: 693-704
176 Pasin L, Navalesi P, Zangrillo A. et al. Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2021; 35 (02) 578-584
177 Torres A, Motos A, Cillóniz C. et al; CIBERESUCICOVID Project Investigators. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med 2022; 48 (07) 850-864
178 Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season. MMWR Recomm Rep [Internet] 2021 [cited Feb 15, 2022]. Accessed November 20, 2023 at: https://www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm
179 Commissioner of the FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine [Internet]. FDA; 2023 [cited May 14, 2023]. Accessed November 20, 2023 at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine
180 U.S. FDA Approves ABRYSVO™, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults | Pfizer [Internet]. [cited July 19, 2023]. Accessed November 20, 2023 at: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention
181 Walsh EE, Pérez Marc G, Zareba AM. et al; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV Prefusion F Vaccine in older adults. N Engl J Med 2023; 388 (16) 1465-1477
182 Papi A, Ison MG, Langley JM. et al; AReSVi-006 Study Group. Respiratory syncytial virus Prefusion F protein vaccine in older adults. N Engl J Med 2023; 388 (07) 595-608
183 EMA. COVID-19 vaccines [Internet]. European Medicines Agency 2021 [cited Feb 15, 2022]. Accessed November 20, 2023 at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
184 COVID-19 Vaccination [Internet]. Centers for Disease Control and Prevention 2023 [cited May 14, 2023]. Accessed November 20, 2023 at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
185 Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA 2021; 325 (13) 1318-1320
186 Nussbaumer-Streit B, Mayr V, Dobrescu AI. et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 9 (09) CD013574
187 Eikenberry SE, Mancuso M, Iboi E. et al. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model 2020; 5: 293-308
188 Liang M, Gao L, Cheng C. et al. Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis. Travel Med Infect Dis 2020; 36: 101751
189 Metersky ML, Aliberti S, Feldman C. et al. Never let a good crisis go to waste. Chest 2021; 159 (03) 917-919
190 Miller SL, Nazaroff WW, Jimenez JL. et al. Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. Indoor Air 2021; 31 (02) 314-323
191 Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med 2020; 8 (07) 658-659